[Expression of the apoptosis inhibitor soluble Fas antigen in patients with malignant and benign bone neoplasms].
This paper presents results of comparative enzyme immunoassay of soluble serum Fas antigen (sFas) in 98 patients with benign and malignant bone tumors, 15 patients with mechanical bone traumas, and 60 normal individuals of compatible age. The prevalence and concentration of sFas were significantly greater in patients with bone tumors than in normal donors and patients with mechanical bone traumas. The association of sFas with the pathogenesis of primary bone tumors is discussed in the paper.
Kushlinskiĭ
N E
NE
Solov'ev
Iu N
IuN
Babkina
I V
IV
Abbasova
S G
SG
Kostanian
I A
IA
Lipkin
V M
VM
Trapeznikov
N N
NN
D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012995:Solubility; D019014:fas Receptor / Q000097:blood*
D014408:Biomarkers, Tumor; D019014:fas Receptor